First patient dose in the Phase 1/2 clinical trial expected in mid-2023BOSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics,…
Acquisition Transforms the Company into a Broader Pharmaceutical Company Spanning Multiple Sectors Company Announces Corporate Name Change to Underscore Broader…
CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on…
Addition of new therapeutic expert reflects company’s commitment to drug development in hematologyDURHAM, N.C., April 19, 2023 (GLOBE NEWSWIRE) --…
Single and repeat dosing of UNO improves outcomes compared to checkpoint inhibitor monotherapy in the aggressive 4T1 breast cancer model…
SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), announced new preclinical data at…
Data further characterize narazaciclib’s mechanism of action and show its anti-cancer activity comparing favorably to that of FDA-approved CDK 4/6…
MIAMI, FL, April 19, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines…
Findings from a mouse model of peritoneally disseminated ovarian cancer suggest biweekly dosing regimen for further evaluation in human clinical…
TNF is involved in the development of Alzheimer’s Disease pathology following traumatic brain injury and is prevented by neutralization of soluble TNF by XPRO™ Boca Raton, Florida, April 19,…